北京若生智能科技有限公司
Drug Database
BE

beclometasone dipropionate (Aerobec / Junik / Ventolair)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · 小分子

什么是 beclometasone dipropionate？

beclometasone dipropionate 是一种小分子，由Teva Pharmaceutical Industries Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Inhaled。

药物档案

商品名Aerobec, Junik, Ventolair
公司Teva Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点NR3C1
给药途径Inhaled
状态Approved
来源： ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

作用机制

分子靶点

beclometasone dipropionate 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

beclometasone dipropionate 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedAdvances in respiratory medicine2026-10-26

Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD.

Kopitovic Ivan I, Dimic-Janjic Sanja S, Stjepanovic Mihailo M, Hromis Sanja S et al.

Single-inhaler triple therapy (SITT) combines an inhaled corticosteroid (ICS; for example, fluticasone furoate, budesonide, or beclometasone dipropionate), a long-acting β2-agonist (LABA; for example, vilanterol or formoterol fumarate), and a long-acting muscarinic antagonist (LAMA; for example, umeclidinium or glycopyrronium bromide) in one device. Triple pharmacological therapy reduces exacerbations in selected patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and cardiovascular outcomes remain uncertain. This structured narrative review summarizes randomized trials, observational comparative-effectiveness studies, target trial emulations, systematic reviews, and health technology assessments published between 2015 and 2026. We grouped the evidence by comparator: LABA/LAMA, ICS/LABA, multiple-inhaler triple therapy (MITT), and ICS continuation versus withdrawal, because each comparison addresses a different clinical question. Pivotal trials and evidence syntheses consistently showed fewer moderate-to-severe exacerbations with triple therapy, with reported rate ratios of approximately 0.69-0.93. Mortality signals from IMPACT and ETHOS are clinically important, but previous ICS use and ICS withdrawal among participants assigned to ICS-free comparators make these findings difficult to interpret. Observational cardiovascular findings are also uncertain because residual confounding, treatment selection, exposure misclassification, outcome misclassification, and differences in baseline disease severity limit causal interpretation. Compared with MITT, the main advantages of SITT are simpler treatment and possible improvements in adherence and persistence, not greater pharmacological potency. Treatment decisions should consider exacerbation history, repeated blood eosinophil counts, pneumonia risk, cardiovascular disease, previous ICS exposure and response, inhaler technique, device suitability, and patient preference. Trials in patients with documented absence of previous ICS use and well-designed target trial emulations are needed to determine whether the observed mortality and cardiovascular associations are causal.

PMID 42930048
阅读全文 →
PubMedJournal of thoracic disease2026-10-13

Symptoms improvement and lung function benefits of fixed triple therapy with beclomethasone/formoterol/glycopyrronium inhalation powder in patients with moderate-to-severe COPD: outcomes of the Bulgarian arm of the RESPONSE study.

Petkov Rosen E RE, Kenderov Andrey N AN, Rodopska Neli L NL, Mekov Evgeni V EV et al.

The fixed triple beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/GB) therapy is available in both pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI) formulations for chronic obstructive pulmonary disease (COPD) treatment. While the pMDI form has been extensively investigated in pivotal trials and real-world studies, real-world data on the DPI (88/5/9 μg) formulation remain limited. The RESPONSE study assessed the real-world effectiveness of BDP/FF/GB inhalation powder in a cohort of moderate-to-severe COPD patients uncontrolled with dual combinations. This non-interventional, prospective, multicenter study was conducted across 21 Bulgarian sites. COPD patients (≥35 years) with persistent symptoms [COPD Assessment Tool (CAT) ≥10 and/or modified Medical Research Council (mMRC) ≥2] and moderate or severe pulmonary obstruction [30%≤ forced expiratory volume in 1 second as a percentage of predicted value (FEV1%) <80%] despite dual therapies were switched to BDP/FF/GB DPI and followed for 6 months. The primary endpoint was improvement in CAT scores. Secondary endpoints included lung function, treatment adherence, dyspnea and the percentage of patients achieving CAT score reduction ≥2 from baseline. A total of 363 patients completed the study. Mean CAT scores improved significantly from 23.0 at baseline to 16.9 (P<0.001), regardless of prior dual therapy or inhaler type. Mean (± SD) FEV1% increased from 47.6%±11.9% to 53.2%±15.75% (P<0.001). Treatment adherence and dyspnea also showed significant improvement. Notably, 87.9% of participants achieved a CAT score reduction ≥2 points. The RESPONSE study showed that switching to BDP/FF/GB DPI was associated with clinically meaningful improvements in symptoms, lung function, and adherence in COPD patients inadequately controlled on dual therapy, supporting its role as a practical escalation option in routine care.

PMID 42865803
阅读全文 →
PubMedAnnals of dermatology2026-10-08

Efficacy of Calcipotriol/Betamethasone Ointment in the Management of Pediatric Alopecia Areata.

Won Yumi Y, Lee Jungsoo J, Kim Hoonsoo H, Ko Hyunchang H et al.

Topical corticosteroids are acknowledged as the first-line treatment for pediatric alopecia areata. There are cases that are recalcitrant to topical corticosteroid application. The objective was to evaluate the efficacy of calcipotriol/betamethasone ointment in pediatric alopecia areata. In a 12-week retrospective study, 40 patients under 10 years old with alopecia areata were included. The patients were treated with a topical ointment combining 0.005% calcipotriol and betamethasone dipropionate once daily. The efficacy was monitored through changes in Severity of Alopecia Tool (SALT) scores. The 40 patients, with a mean age of 4.1±2.1 years, were categorized by their SALT scores into two groups: those above and below 50. Patients with SALT scores over 50 showed hair regrowth in 7.44±4.44 weeks, while those with SALT scores under 50 showed regrowth in 5.71±2.58 weeks. After 12 weeks, 80.0% of the patients showed hair regrowth and 20.0% of patients showed no response or worsening. Only minor adverse events were documented during follow-up. Calcipotriol/betamethasone ointment may represent a useful topical option for pediatric alopecia areata.

PMID 42845204
阅读全文 →
PubMedRespiratory medicine2026-10-05

Early versus late escalation to extrafine BDP/FF/GB single-inhaler triple therapy in COPD: a real-world subgroup analysis by disease duration since diagnosis.

Rogliani Paola P, Brusselle Guy G, Stolz Daiana D, Piraino Alessio A et al.

The optimal timing for escalation to triple therapy in chronic obstructive pulmonary disease (COPD) remains undefined, often resulting in delayed treatment. Consequently, evidence on the effectiveness of early initiation is limited. This subgroup analysis used pooled patient-level data from six observational studies to evaluate the real-world effectiveness of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide single-inhaler triple therapy (SITT) in COPD according to disease duration. Patients were stratified into three subgroups: ≤48 months (short), 49-96 months (intermediate), and ≥97 months (long-standing). Outcomes assessed at 3, 6, and 12 months post-SITT initiation included mean number of exacerbations, proportion of patients experiencing ≥1 exacerbation, and proportion achieving disease stability and control. Mean number of exacerbations decreased from the year prior to SITT initiation at all post-treatment time points across all subgroups, with the largest reductions observed in short disease patients, particularly at 12 months. Similarly, the proportion of patients experiencing ≥1 exacerbation decreased in all subgroups, with the lowest proportions observed in short disease patients. No differences between subgroups were observed at 3 and 6 months in the proportion of patients achieving disease stability and control; conversely, at 12 months the short disease subgroup showed significantly higher rates of disease stability and control compared with longer disease duration subgroups, suggesting that earlier SITT initiation may provide more sustained benefits. Early escalation to SITT in COPD may result in more durable sustained clinical benefits compared with later intervention, reducing exacerbations and maintaining disease stability and control up to 12 months.

PMID 42833477
阅读全文 →
PubMedCase reports in dermatology2026-09-30

A New Restrictive Composite Endpoint to Assess Best Response in Patients with Mild-to-Moderate Psoriasis Treated with CAL/BDP PAD Cream: A Case Series.

Pinter Andreas A, Galván Jordi J, Freischläger Frank F

In the assessment of a psoriasis treatment, traditional endpoints evaluated independently may not fully capture the multidimensional nature of treatment response. Best response to calcipotriol/betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology has recently been defined as a restrictive composite endpoint comprising two efficacy outcomes (Physician's Global Assessment [PGA] 0-1 and modified Psoriasis Area and Severity Index [mPASI] <2) and one quality-of-life outcome (Dermatology Life Quality Index [DLQI] 0-1). This retrospective case series aims to provide further insights into the demographics and outcomes of patients achieving best response to CAL/BDP PAD cream based on this newly defined composite endpoint. From the 213 patients with mild-to-moderate psoriasis who received CAL/BDP PAD cream in the European MC2-01-C7 phase 3 clinical trial (NCT03802344), 7 patients who achieved best response at week 4 and/or week 8 and had available clinical photographs were evaluated. The mean patient age was 55.0 years (range: 34-68), with a mean psoriasis duration of 19.9 years (range: 6.9-29.1). Results support the efficacy of CAL/BDP PAD cream in improving both clinical signs and quality of life. Despite existing variability in key baseline characteristics and long disease duration, all included patients met the novel restrictive composite endpoint after 8 weeks, which reflects complete/almost complete clearance of psoriasis and no impact on patient quality of life.

PMID 42813183
阅读全文 →
PubMedCureus2026-09-27

Rapid Improvement of Refractory Pruritus in Extragenital and Perianal Lichen Sclerosus With Nemolizumab: A Case Report.

Frucht Corey S CS, Ragsdale Bruce D BD

Lichen sclerosus is a chronic inflammatory dermatosis that most commonly affects anogenital skin but may also involve extragenital sites. Pruritus can be severe and may persist despite standard anti-inflammatory therapy. Nemolizumab is a monoclonal antibody targeting interleukin-31 receptor alpha, a pathway involved in chronic itch. We report a 68-year-old woman with biopsy-proven lichen sclerosus involving the upper back, chest, shoulders, and perianal area, with several truncal lesions localizing to surgical scars from prior post-bariatric body-contouring surgery. She reported remote genital involvement several years earlier. At the eight-week follow-up, shiny white plaques involved the perianal area, but no vulvar involvement was identified. The patient had severe pruritus affecting sleep and daytime function. Prior treatments included betamethasone dipropionate 0.05% cream, intralesional triamcinolone acetonide, and office-based narrowband ultraviolet B phototherapy, the latter producing remission from 2021 until early 2026 before recurrence. Because of recurrent severe pruritus, nemolizumab was started off-label with a 60 mg subcutaneous loading dose followed by 30 mg every four weeks. No other topical, systemic, or phototherapy treatment was used after nemolizumab initiation through the first eight weeks. At four-week follow-up, patient-reported pruritus improved from 8/10 to 0/10. At eight-week follow-up, pruritus remained markedly improved, although she reported a transient flare of burning in the perianal area several weeks earlier that had since markedly improved. No adverse effects occurred. Examination continued to show shiny white plaques, including perianal involvement, without clear morphologic remission. A short pulse of clobetasol 0.05% ointment was initiated for perianal disease at the eight-week visit while nemolizumab was continued. This case suggests that nemolizumab may provide rapid symptomatic relief of refractory pruritus associated with lichen sclerosus, even without early morphologic resolution.

PMID 42799185
阅读全文 →

注册免费账户还可查看另外 3764 篇文献

免费注册查看全部文献 →

了解更多beclometasone dipropionate